The weekly litigation news digest is live. Subscribe now

IP Verse

Novel Fgfr3 Fusion Product - EP2824181

The patent EP2824181 was granted to Astellas Pharma on Nov 14, 2018. The application was filed on Mar 7, 2013 under application number EP13757006A. The patent is currently recorded with a legal status of "Revoked".

EP2824181

ASTELLAS PHARMA
Application Number
EP13757006A
Filing Date
Mar 7, 2013
Status
Revoked
May 26, 2023
Publication Date
Nov 14, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
BOULT WADE TENNANTAug 14, 2019BOULT WADE TENNANTADMISSIBLE
JAMES POOLEAug 12, 2019CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2008075068
DESCRIPTIONWO2010129509
SEARCHEP2821402
SEARCHWO2014018673
SEARCHWO2014071419

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents